top of page

Enrolling Clinical Studies

Smiling Doctor


We’re currently conducting a Clinical Trial for adults diagnosed with Urticaria, evaluating a new study-treatment. This study will assess the efficacy and safety of Barzolvolimab, a monoclonal antibody subcutaneous injection, in patients with Chronic Spontaneous Urticaria (chronic hives, red itchy bumps or welts on the skin) who remain symptomatic despite antihistamine treatment.

  • Men or Women 18 years of age or older.

  • Have a diagnosis of Chronic Spontaneous Urticaria 6 months or more prior screening.

  • Presence of active welts with swelling during the screening visit.

  • No history of other skin diseases with chronic itching e.g., psoriasis, atopic dermatitis.

  • Have not received a vaccine within 2 months prior screening: rubella, chicken pox, yellow fever

  • No history of chronic diseases e.g., hepatic, renal disease, diabetes, severe asthma, COPD, HIV.

  • No participants with active infection requiring treatment with antibiotics, antivirals, antifungals.

  • Not women who are pregnant of nursing prior study treatment.

  • Not using prohibited medications during screening, study treatment and follow-up.

Study Duration:

This study contains a total of 7 in-clinic visits over a period of 24 weeks.


Financial compensation for time & transportation may be provided

bottom of page